[Document name] Claims

[Claim 1] An ointment produced by mixing a self-magnetic metal-salen complex compound, in which a metal atom part in each of multiple molecules of a metal-salen complex or a derivative of the metal-salen complex is multimerized via water, with a base.

[Claim 2] The ointment according to claim 1, wherein the multiple molecules are two molecules and the metal atom part of each of the two molecules is dimerized via water.

[Claim 3] An ointment produced by mixing a self-magnetic metal-salen complex compound expressed by any one of the following Formulas (I), (II), and (III) with a base:

Formula (I)



Formula (II)



(4)



(where R_2 represents a plurality of nucleic acids which are combined together and are formed of adenine, guanine, thymine, cytosine, or uracil);

(5) -NHCOH, $-NH_2$, $-NHR_1$, or, $-NR_1R_2$

(where R_1 and R_2 are alkyl or alkane with the same carbon number or the carbon number from 1 to 6);

(6) $-NHR_3$-, $-NHCOR_3$, or, $-R_3$

(where R_3 represents a substituent bound as a result of desorption of a functional group such as hydrogen or a hydroxyl group); and

(7) halogen atoms such as chlorine, bromine, or fluorine.

[Claim 4] The ointment according to claim 3, wherein charge transfer of R_3 is less than 0.5 electrons (e).

[Claim 5] The ointment according to claim 3 or claim 4, wherein R_3 is any one of compounds represented by the following formulas (1) to (27):



(27) Amino acid (valine)



[Claim 6] A local anesthetic having the self-magnetic metal-salen complex compound described in claim 3, wherein the self-magnetic metal-salen complex compound is mixed with a base to produce an ointment and R_3 is a compound composed of a substituent represented by any one of the following formulas (28) to (38) obtained as a result of desorption of hydrogen from a compound which has a methyl group and whose charge transfer is less than 0.5 electors (e):

(28) General name: lidocaine



lidocaine



(35) General name: mepivacaine



(36) General name: p-butylaminobenzoyldiethylaminoethanol hydrochloride



(37) General name: bupivacaine hydrochloride



(38) General name: ropivacaine hydrochloride hydrate



[Claim 7] An antineoplastic drug having any one self-magnetic metal-salen complex compound described in claim 3 or claim 4, wherein the self-magnetic metal-salen complex compound is mixed with a base to produce an ointment and R_3 is any one of compounds represented by the following formulas (39) to (103), which combines with a main skeleton of the compound of the above formula via a linking group part obtained

formula67



[Claim 8] An antineoplastic drug having any one self-magnetic metal-salen complex compound described in claim 3 or claim 4, wherein the self-magnetic metal-salen complex compound is mixed with a base to produce an ointment and R_3 is composed of any one of compounds represented by the following formulas (104) to (109):

(104) Product name: Leuplin; and general name: leuprorelin acetate, anti-tumor agent



(105) Product name: methotrexate; and general name: methotrexate, anti-tumor agent



(106) Product name: Novantrone; and general name: mitoxantrone hydrochloride, anti-tumor agent

ozogamicin, anti-tumor agent



[Claim 9] An ointment produced by mixing a self magnetic metal-salen complex compound, in which at least one of positions a, b, c, d, e, f, g, h, i, j, k, and l of the following compound is bonded to another compound and said another compound is magnetized, with a base:



where M represents Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir, Pt, Nd, Sm, Eu, or Gd.

[Claim 10] An ointment characterized in that any one of the compounds described in any one of claim 1 to claim 9 is mixed at a rate of 0.01 wt% to 10 wt% with a base.